Apotex's Ruxolitinib ANDA Filing and Approval Timeline
Apotex filed its Abbreviated New Drug Application (ANDA) for a generic version of Incyte/BMS's Jakafi (ruxolitinib) on May 11, 2018, under Paragraph IV, challenging patents listed in the Orange Book.[1][2]
The FDA approved the ANDA on November 22, 2023, granting 180-day generic exclusivity to Apotex and its co-developer, Lupin.[1][3]
This marks a pendency of 5 years, 6 months, and 11 days (from May 11, 2018, to November 22, 2023).
Why Did Approval Take Over 5 Years?
Paragraph IV challenges trigger 30-month patent litigation stays. Incyte/BMS sued Apotex in Delaware federal court shortly after filing, with the case (Incyte Corp. v. Apotex Inc., 1:18-cv-00944) resolving via settlement in September 2022, lifting the stay.[2][4]
Post-stay, FDA review proceeded amid ongoing patent disputes with other generics, but Apotex cleared key hurdles first.[1]
When Can Apotex Launch Its Generic?
Apotex and Lupin can enter the U.S. market no earlier than May 22, 2024 (180 days after approval), assuming no injunctions from remaining litigation.[1][3]
Commercial launch occurred around that date, with reports of initial shipments in June 2024.[5]
Patent Status and Expiry for Ruxolitinib
Key Jakafi patents expire in 2027-2028, but pediatric exclusivity extends some to August 2028. DrugPatentWatch tracks 18 Orange Book patents, with challenges from 10+ ANDAs.[6]
| Patent | Expiry Date | Status |
|--------|-------------|--------|
| 7,598,257 (composition) | Feb 17, 2027 | Litigated, upheld |
| 8,158,616 (method of use) | Apr 24, 2027 | Multiple challenges |
| RE45,899 (reissue) | Aug 29, 2028* | Primary barrier |
*With pediatric extension.[6]
Apotex carved out some claims but faced full Paragraph IV for others.[2]
Other Ruxolitinib Generics in the Pipeline
- Lupin/Slataper: Co-exclusivity with Apotex; same timeline.
- Teva, Mylan, Sun, Dr. Reddy's: Tentative approvals pending patent resolutions; launches likely 2028+.[6][7]
- Litigation risks persist; Incyte settled with some but fights others.[4]
Market Impact and Pricing Expectations
Jakafi peaked at $2.9B U.S. sales in 2023. Generic entry cut prices ~80% initially, per industry patterns for high-value oncology drugs.[5][8]
Patients report easier access post-launch, though supply chain ramps take 3-6 months.[9]
Sources
[1]: FDA ANDA Approval Letter for Apotex Ruxolitinib
[2]: Court Listener - Incyte v. Apotex Docket
[3]: FDA Orange Book Entry for ANDA 217939
[4]: Law360 - Incyte-Apotex Settlement Coverage
[5]: FiercePharma - Generic Jakafi Launch Report
[6]: DrugPatentWatch.com - Ruxolitinib Patents
[7]: FDA Tentative Approvals List
[8]: IQVIA Sales Data via Evaluate
[9]: Patient Forums & ASHP Alerts